Irritable bowel syndrome subtype predicts treatment response and defines distinct mechanistic phenotypes in OAB-IBS comorbidity: a prospective observational study.

Authors

Qi Sun, Yubo Gao, Xinhang Shi, Ming Xie, Jun Zheng, Xunguo Yang, Lin Yang, Rulin Liao, Cunzhen Ma, Zhuohang Li, Boyuan Sun, Bisheng Cheng, Peng Wu

Published in

World journal of urology. Volume 44. Issue 1. Jun 25, 2026. Epub Jun 25, 2026.

Abstract

To investigate the heterogeneity of treatment response in patients with concomitant Overactive Bladder (OAB) syndrome and Irritable Bowel Syndrome (IBS), including diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), and mixed-type (IBS-M), by stratifying outcomes by both treatment strategy and IBS subtype. We hypothesized that IBS subtype would predict therapeutic response and define distinct mechanistic phenotypes.
In this prospective, observational cohort study (N = 144, screened from 259), patients were allocated to one of four non-randomized cohorts: OAB-Targeted Monotherapy (OAB-TM, n = 45), OAB-Targeted Dual Therapy (OAB-TD, n = 29), IBS-Targeted Monotherapy (IBS-TM, n = 47), or IBS-Targeted Dual Therapy (IBS-TD, n = 23). Outcomes included changes in OABSS, IBS-SSS, PHQ-9, GAD-7, and QOL scores over 8 weeks. Efficacy was compared using ANCOVA, adjusted for baseline scores. Objective data from uroflowmetry parameters and baseline predictors of response were analyzed.
Dual therapy demonstrated superior improvement over monotherapy across all symptom, mood, and QOL domains. However, stratified analysis revealed significant heterogeneity. In the IBS-targeted cohort, the superiority of dual therapy for OAB improvement was highly significant in the IBS-D subtype but not in IBS-M or IBS-C subtypes. This corresponded to distinct baseline uroflowmetry parameters: IBS-D patients typically showed high-peak tower-shaped curves, while IBS-C patients showed staccato patterns. Furthermore, baseline anxiety (GAD-7) and depression (PHQ-9) scores significantly predicted OAB cross-organ improvement in the IBS-TM cohort.
OAB-IBS comorbidity is not a monolithic entity but comprises distinct clinical phenotypes (pelvic floor-driven, central sensitization-driven, bladder-primary). These findings suggest that a uniform treatment protocol may be suboptimal, supporting a precision-medicine framework where management is tailored based on the patient's specific IBS subtype.

PMID:
42347939
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.